The present invention relates to a method of producing an E. coli vaccine and to the vaccine produced thereby. The method involves purifying lipopolysaccharide from E. coli expressing complete O-polysaccharide sidechains;isolating the O-polysaccharide region of the lipopolysaccharide molecule by hydrolysis in dilute acetic acid and purifying it essentially free of lipid A; and covalently coupling lipid A-free O-polysaccharide via at least one hydroxyl or carboxyl group of the polysaccharide to a carrier protein. Polyvalent vaccines are prepared by combining two or more monovalent vaccines for different serotypes prepared according to the present invention. The present also relates to conjugates used in the vaccines. The conjugates of the present invention are the O-polysaccharide region of an E. coli lipoplysaccharide molecule covalently coupled to a carrier protein.
The application discloses a method for the treatment of Heliobacter infection in a mammalian host, which comprises administration to said infected host of an immunologically effective amount of one or more Heliobacter antigen(s), optionally in association with a mucosal adjuvant.
A general method of producing an immunogenic product consisting of antigenically active carbohydrate moieties (ACM) which each are covalently coupled via identical divalent bridge groups to immunologically active carriers (IAC) containing amino groups, is disclosed. The immunogenic product comprises a divalent bridge group which has structural formula (I). In addition to the immunogenic product, the invention also comprises use of said product as immunizing component. ##STR1##
The application discloses a method for the treatment of Heliobacter infection in a mammalian host, which comprises administration to said infected host of an immunologically effective amount of one or more Heliobacter antigen(s), optionally in association with a mucosal adjuvant.
Compositions and methods for making complex carbohydrates in a bacterial production cell are disclosed. The complex carbohydrates that can be made include oligosaccharides and polysaccharides of bacterial or mammalian origin.
An oligosaccharide derived from an antigen polysaccharide obtained from a pathogenic agent, a method for its preparation, and its use particularly as a vaccinal agent. The oligosaccharide is prepared by oxidation-reduction depolymerization reaction.
